<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01902030</url>
  </required_header>
  <id_info>
    <org_study_id>ASP PCR IA TISSUE-EFFUSION</org_study_id>
    <nct_id>NCT01902030</nct_id>
  </id_info>
  <brief_title>Evaluation of Performance of An Aspergillus PCR in Tissue and Pleural Effusion Samples of Immunocompromised Patients</brief_title>
  <official_title>Diagnostic Study of Performance of an Aspergillus Specific Polymerase Chain Reaction in Tissue and Pleural Effusion Samples of Immunocompromised Patients for the Diagnosis of Invasive Aspergillosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although being a frequent and lethal complication in patients (pts) with hematologic
      malignancies, diagnosing invasive aspergillosis (IA) still remains a difficult issue as
      culture-based methods show low sensitivity especially under the current clinical practice of
      antifungal prophylaxis or rapid antifungal therapy. In certain clinical settings, performing
      biopsies for identification of the underlying infectious organism becomes important. However,
      as culture-based methods only yield results in a minority of patients, using
      non-culture-based methods like Aspergillus specific polymerase chain reaction (PCR) for
      detection of IA directly in clinical specimens is becoming increasingly important and might
      help to characterize the causative pathogen.

      Therefore the performance of an established Aspergillus-specific nested PCR in biopsies,
      re-section material or pleural effusions is evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Calculation of sensitivity, Specificity, positive predictive value, negative predictive value and diagnostic odds ratio</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluation of Sensitivity, Specificity, positive predictive value, negative predictive value and diagnostic odds ratio of aspergillus specific PCR in tissue and effusion samples by comparing the population with proven / probable invasive aspergillosis with patients suffering from No IA according to recent EORTC/MSG criteria of PCR in Biopsies/Effusion samples of Patients</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Aspergillosis</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>Proven/Probable IA Patients</arm_group_label>
    <description>Case Population</description>
  </arm_group>
  <arm_group>
    <arm_group_label>possible/No IA Patients</arm_group_label>
    <description>Control population</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fungal DNA, no human DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  Immunocompromised individuals with suspicion of harbouring an invasive fungal
             infection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Immunocompromised individuals with suspicion of harbouring an invasive fungal
             infection

          -  Definition by 2008 EORTC/MSG Criteria (de Pauw CID 2008)

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Buchheidt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cologne University Hospital</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duesseldorf University Hospital</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eschweiler General Hospital</name>
      <address>
        <city>Eschweiler</city>
        <zip>52249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frankfurt (Oder) General Hospital</name>
      <address>
        <city>Frankfurt (Oder)</city>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freiburg University Hospital</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Halle University Hospital</name>
      <address>
        <city>Halle (Saale)</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik at Heidelberg University Hospital</name>
      <address>
        <city>Heidelberg</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Herne</name>
      <address>
        <city>Herne</city>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mannheim University Hospital</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prosper Hospital Recklinghausen</name>
      <address>
        <city>Recklinghausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wiesbaden Bone Marrow transplantation center</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuerzburg University Hospital</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Spiess B, Seifarth W, Hummel M, Frank O, Fabarius A, Zheng C, MÃ¶rz H, Hehlmann R, Buchheidt D. DNA microarray-based detection and identification of fungal pathogens in clinical samples from neutropenic patients. J Clin Microbiol. 2007 Nov;45(11):3743-53. Epub 2007 Aug 22.</citation>
    <PMID>17715373</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2013</study_first_submitted>
  <study_first_submitted_qc>July 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2013</study_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Dieter Buchheidt</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion</mesh_term>
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

